Biowave
Norwalk
About Biowave
BioWave is a patented smarter pain blocking technology that delivers therapeutic electrical signals through skin into deep tissue right to the surface of pain fibers. The electrical field that forms around the pain fibers blocks the transmission of pain signals to the brain. The mechanism of action is similar to a chemical anesthetic like Novocain, except BioWave is blocking the transmission of the pain signal electrically instead of chemically. Because the pain signal is blocked at the nerve inside the body, a 30 minute treatment can provide up to 24 hours of continued pain relief. And there is a cumulative benefit with multiple treatments. BioWave manufactures and sells 3 medical device systems, BioWavePRO (Rx), BioWaveHOME (Rx) and BioWaveGO (OTC) and two types of disposables - sterile single use percutaneous electrodes and reusable noninvasive electrodes. More information is available at biowave.com.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Estimated revenue: $1K – $10K
- Total funding: $3.1M
- Last round: Series Unknown (Jan 2020)
- Website: biowave.com
- Phone: 1-877-BIOWAVE (1-877-246-9283)
Industries & Categories
Biotechnology, Health Care, Manufacturing, Medical, Medical Device
Social Profiles
Canonical: https://fsome.com/organization/biowave-141658 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.